Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response

The Journal of Antimicrobial Chemotherapy
Charlotte CharpentierDiane Descamps

Abstract

To assess the prevalence of minority resistant variants (MRVs) at baseline and their impact on the virological response. The ANRS 139 TRIO trial evaluated the combination of raltegravir, etravirine and darunavir, plus an optimized background therapy, in 87% of cases. Patients were highly experienced and harboured multiresistant viruses, but were naive to the three drugs, and showed a high level of virological suppression. Ultra-deep sequencing of reverse transcriptase, protease and integrase regions was performed at the trial baseline, and sequences were interpreted according to the ANRS algorithm. MRVs were assessed using MiSeq and 454 technologies (limit of detection 1%). At baseline, minority variants with at least one NRTI, one NNRTI, one PI, one major PI or an integrase inhibitor resistance-associated mutation were present in 46%, 45%, 68%, 24% and 13% of patients, respectively. When minority variants are taken into account, the prevalence of resistance to etravirine, darunavir and raltegravir at baseline was 29%, 40% and 9%, respectively. No difference was observed in the prevalence of MRVs between patients with virological failure and those with virological success, except a trend for patients exhibiting baseline etravir...Continue Reading

References

Aug 30, 2008·Proceedings of the National Academy of Sciences of the United States of America·Peter J CampbellMichael R Stratton
Oct 10, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Y YazdanpanahUNKNOWN ANRS 139 TRIO Trial Group
Aug 31, 2010·AIDS·Charlotte CharpentierUNKNOWN ANRS 139 TRIO Trial study group
Apr 7, 2011·JAMA : the Journal of the American Medical Association·Jonathan Z LiDaniel R Kuritzkes
Feb 2, 2012·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Catherine FagardUNKNOWN ANRS 139 TRIO Trial Group
Mar 19, 2013·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Christophe RodriguezJean-Michel Pawlotsky
Jun 1, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Christian PouRoger Paredes
Oct 23, 2014·The Journal of Antimicrobial Chemotherapy·Alessandro Cozzi-LepriUNKNOWN CHAIN Minority HIV-1 Variants Working Group

❮ Previous
Next ❯

Citations

Jun 27, 2015·Current Opinion in Virology·Kristel Van LaethemAnne-Mieke Vandamme
Nov 8, 2016·Virus Research·Maria Casadellà, Roger Paredes
Jul 1, 2017·Journal of Clinical Microbiology·Aubin J NanfackRalf Duerr

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.